Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Annual Report

News

Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment

Published November 20, 2008, 12:39 am, Presseportal

Cork, Ireland, November 20 (ots/PRNewswire) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir (VX-950), an investigational protease ...

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Annual Report Stories

From Various News Sources

Tibotec begins enrollment for Phase III study of telaprevir - EurekAlert
- REALIZE is the first phase III study to evaluate a specifically targeted antiviral therapy for hepatitis C (STAT-C) across a full range of HCV-patients who failed prior treatment to current standard of care, including null responders - MECHELEN ...

Tibotec Begins Enrollment For Phase III Study Of Telaprevir, An ... - Medical News Today
Tibotec BVBA announced that it has begun enrolling patients in its phase III clinical trial evaluating telaprevir, an investigational hepatitis C virus protease inhibitor, in patients who failed prior therapy with peginterferon (Peg-IFN) plus ...

Related Social Bookmarks

None found at this time.